PapersFlow Research Brief
Drug-Induced Adverse Reactions
Research Guide
What is Drug-Induced Adverse Reactions?
Drug-Induced Adverse Reactions are hypersensitivity reactions to medications, including severe cutaneous disorders like Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, often linked to specific HLA genotypes such as HLA-B*5701, HLA-B*1502, and HLA-B*5801.
This field encompasses 65,714 papers on drug hypersensitivity, including drug-induced hypersensitivity syndrome (DIHS), delayed reactions, and genetic screening for prevention. "HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008) demonstrated that screening reduced abacavir hypersensitivity risk, with 94% of screened patients in white populations lacking the allele and facing low risk. "Severe Adverse Cutaneous Reactions to Drugs" (Roujeau and Stern, 1994) noted these reactions occur at low rates but can lead to death or disability, prompting changes in drug recommendations.
Topic Hierarchy
Research Sub-Topics
HLA-B*5701 Screening for Abacavir Hypersensitivity
This sub-topic examines the genetic association between HLA-B*5701 allele and abacavir-induced hypersensitivity reactions, focusing on screening protocols to prevent severe adverse events in HIV patients. Researchers study validation of genotyping methods, cost-effectiveness analyses, and implementation in clinical guidelines.
HLA-B*1502 and Carbamazepine-Induced Stevens-Johnson Syndrome
This sub-topic investigates the link between HLA-B*1502 genotype and carbamazepine-triggered Stevens-Johnson Syndrome (SJS), particularly in Asian populations. Researchers analyze population-specific risks, mechanistic pathways, and preventive genotyping strategies.
HLA-B*5801 Association with Allopurinol Hypersensitivity
This sub-topic explores the role of HLA-B*5801 in allopurinol-induced severe cutaneous adverse reactions like SJS and Toxic Epidermal Necrolysis. Researchers focus on risk stratification, alternative therapies for gout patients, and integration into prescribing practices.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
This sub-topic covers the immunopathogenesis, diagnostic criteria, and management of DRESS syndrome triggered by aromatic anticonvulsants and other drugs. Researchers study viral reactivation roles, long-term sequelae, and corticosteroid therapies.
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Classification
This sub-topic addresses clinical scoring systems, histopathological features, and prognostic factors for distinguishing Toxic Epidermal Necrolysis (TEN) from SJS. Researchers evaluate SCORTEN scores, IVIG treatments, and epidemiological patterns.
Why It Matters
Drug-induced adverse reactions impact patient safety in pharmacology by enabling genetic screening to prevent severe outcomes, as shown in "HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008), where HLA-B*5701 testing before abacavir therapy reduced hypersensitivity incidence in clinical trials. In HIV treatment, this screening identifies 94% of low-risk patients in white populations, avoiding reactions like fever and rash. "A marker for Stevens–Johnson syndrome" (Chung et al., 2004) linked HLA-B*1502 to carbamazepine-induced cases, guiding prescribing in at-risk ethnic groups and reducing Stevens-Johnson Syndrome occurrences. "Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose" (Chung et al., 2008) identified IgE antibodies causing anaphylaxis in cancer patients, altering cetuximab use protocols.
Reading Guide
Where to Start
"HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008) because it provides a clear example of successful genetic screening reducing abacavir reactions with quantifiable risk reduction in 94% of low-risk patients.
Key Papers Explained
"HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008) established HLA genotyping for abacavir, building on "Severe Adverse Cutaneous Reactions to Drugs" (Roujeau and Stern, 1994) which outlined low-rate but high-impact skin reactions. "A marker for Stevens–Johnson syndrome" (Chung et al., 2004) extended this by identifying HLA-B*1502 for carbamazepine cases, while "Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme" (Bastuji‐Garin et al., 1993) standardized diagnosis. "Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose" (Chung et al., 2008) added IgE-mediated mechanisms distinct from HLA pathways.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on HLA-B*5701, B*1502, and B*5801 for predicting reactions to abacavir, carbamazepine, and allopurinol, per the cluster description, with no recent preprints or news shifting focus.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and... | 2000 | New England Journal of... | 4.0K | ✓ |
| 2 | Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-... | 2000 | JAMA | 3.2K | ✕ |
| 3 | Sarcoidosis | 2007 | New England Journal of... | 1.9K | ✕ |
| 4 | Statement on Sarcoidosis | 1999 | American Journal of Re... | 1.9K | ✕ |
| 5 | HLA-B*5701 Screening for Hypersensitivity to Abacavir | 2008 | New England Journal of... | 1.8K | ✓ |
| 6 | A marker for Stevens–Johnson syndrome | 2004 | Nature | 1.7K | ✓ |
| 7 | Cremophor EL | 2001 | European Journal of Ca... | 1.6K | ✕ |
| 8 | Clinical Classification of Cases of Toxic Epidermal Necrolysis... | 1993 | Archives of Dermatology | 1.6K | ✕ |
| 9 | Severe Adverse Cutaneous Reactions to Drugs | 1994 | New England Journal of... | 1.5K | ✕ |
| 10 | Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α... | 2008 | New England Journal of... | 1.5K | ✓ |
Frequently Asked Questions
What role does HLA-B*5701 play in abacavir reactions?
HLA-B*5701 screening reduces hypersensitivity to abacavir, as 94% of patients without the allele in white populations face low risk. "HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008) confirmed this pharmacogenetic approach lowers reaction incidence before therapy starts.
How are Stevens-Johnson Syndrome cases classified?
Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme are standardized using an illustrated atlas for drug- or infection-attributed bullous disorders. "Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme" (Bastuji‐Garin et al., 1993) proposes five categories to aid diagnosis.
What causes cetuximab anaphylaxis?
Cetuximab-induced anaphylaxis stems from IgE antibodies specific to galactose-α-1,3-galactose present in patient serum before therapy. "Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose" (Chung et al., 2008) detected these antibodies in most reacting subjects.
Why screen for HLA alleles in severe cutaneous reactions?
Specific HLA genotypes like HLA-B*5701 predict severe reactions to drugs such as abacavir, carbamazepine, and allopurinol. "Severe Adverse Cutaneous Reactions to Drugs" (Roujeau and Stern, 1994) highlighted how even few cases linked to a drug alter usage guidelines.
How do COX-2 inhibitors compare to NSAIDs in GI toxicity?
Rofecoxib showed fewer upper gastrointestinal events than naproxen in rheumatoid arthritis patients. "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis" (Bombardier et al., 2000) reported this reduction in clinically important events.
Open Research Questions
- ? How can HLA genotyping expand beyond HLA-B*5701, B*1502, and B*5801 to predict reactions for more drugs?
- ? What etiologic distinctions exist among the five categories of bullous skin disorders in drug reactions?
- ? Can pre-therapy IgE testing for galactose-α-1,3-galactose prevent cetuximab anaphylaxis across populations?
- ? What mechanisms link Cremophor EL to hypersensitivity in chemotherapy?
- ? How do environmental factors interact with HLA predispositions in drug-induced sarcoidosis-like reactions?
Recent Trends
The field holds steady at 65,714 papers with no 5-year growth data available; emphasis remains on HLA-B*5701 screening from "HLA-B*5701 Screening for Hypersensitivity to Abacavir" (Mallal et al., 2008) and markers like HLA-B*1502 in "A marker for Stevens–Johnson syndrome" (Chung et al., 2004), as no preprints or news from the last 12 months indicate changes.
Research Drug-Induced Adverse Reactions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Drug-Induced Adverse Reactions with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers